Machinify Expands Payment Intelligence Platform with Genetic Testing Expertise to Improve Healthcare Payment Accuracy
Machinify has announced the expansion of its AI-powered healthcare payment intelligence platform with a new genetic testing capability, marking a significant step in addressing one of the fastest-growing and most clinically complex areas of modern healthcare. The enhancement enables health plans to evaluate genetic testing claims with greater clinical precision and payment accuracy while helping organizations navigate the rapidly evolving landscape of precision medicine.
The new capability extends Machinify’s artificial intelligence platform into genetic testing payment integrity, allowing insurers and healthcare payers to make more informed reimbursement decisions across the payment lifecycle. By combining advanced AI with decades of specialized clinical expertise, the company aims to improve payment accuracy, reduce unnecessary healthcare spending, and strengthen compliance with evolving coverage policies.
As genetic testing becomes increasingly central to personalized medicine, healthcare organizations face mounting challenges in reviewing claims accurately and consistently. Machinify’s latest innovation is designed to address these challenges by automating complex payment decisions while maintaining transparency, clinical rigor, and auditability.
Meeting the Growing Demands of Precision Medicine
Precision medicine has transformed healthcare by enabling physicians to tailor prevention, diagnosis, and treatment strategies according to an individual’s genetic profile.
Advances in genomic science have expanded the availability of genetic tests capable of identifying inherited disorders, predicting disease risk, guiding targeted therapies, and improving medication selection.
The field continues to evolve at an extraordinary pace.
Today, more than 150,000 genetic tests are available worldwide, with over ten new tests entering the market every day. This rapid growth reflects ongoing scientific discoveries across oncology, reproductive medicine, pharmacogenomics, rare diseases, cardiovascular medicine, neurology, and numerous other clinical specialties.
While these innovations offer significant benefits for patient care, they also introduce unprecedented complexity into healthcare reimbursement systems.
Health plans must evaluate an expanding number of tests, each with unique clinical indications, coding requirements, coverage criteria, and supporting evidence.
Managing these variables manually has become increasingly difficult.
The Challenge of Genetic Testing Payment Integrity
Unlike many traditional laboratory services, genetic testing often requires detailed clinical interpretation before reimbursement decisions can be made.
Coverage may depend on multiple factors, including:
- Patient diagnosis
- Family medical history
- Clinical indications
- Physician documentation
- Medical necessity
- Current clinical guidelines
- Payer-specific coverage policies
- Test methodology
- Applicable billing codes
As scientific evidence evolves, payer policies must also be updated regularly to reflect new research findings and regulatory guidance.
Keeping pace with these changes represents a significant operational burden for health plans.
Traditional payment integrity programs often rely heavily on manual review processes that struggle to scale alongside the growing complexity of precision medicine.
This creates opportunities for both inappropriate claim denials and incorrect payments.
Machinify’s new genetic testing capability has been developed specifically to address these challenges.
Expanding AI Across the Payment Lifecycle
The addition of genetic testing expertise represents another milestone in Machinify’s broader strategy of applying artificial intelligence to increasingly sophisticated healthcare payment decisions.
Rather than functioning as a standalone review tool, the new capability integrates directly into the company’s existing payment intelligence platform.
This allows AI models to evaluate genetic testing claims within the broader clinical and contractual context of each patient’s healthcare encounter.
The platform supports both:
- Real-time pre-payment claim review
- Post-payment retrospective analysis and recovery
By operating across multiple stages of the payment lifecycle, Machinify enables health plans to prevent incorrect payments before claims are processed while also identifying overpayments after reimbursement has occurred.
This dual approach helps improve financial performance while reducing administrative burden.
Building on Specialized Clinical Expertise
The new capability builds upon Machinify’s acquisition of InformedDNA’s genetic testing payment integrity business.
That acquisition brought decades of specialized clinical knowledge into the company’s AI platform.
Rather than simply automating existing workflows, Machinify has incorporated extensive genetic testing expertise directly into its machine learning models.
This enables the AI system to evaluate claims using principles similar to those applied by experienced genetic specialists.
The platform continuously integrates evolving clinical evidence alongside payer-specific policies, allowing reimbursement decisions to remain aligned with current standards of care.
This combination of human expertise and artificial intelligence provides a foundation for more accurate and consistent payment determinations.
AI Designed to Reason Like Clinical Experts
Machinify Chief Executive Officer David Pierre emphasized that the company’s objective extends beyond creating another software tool for reviewing genetic tests.
Instead, the company has trained its AI models to reason through genetic testing decisions in much the same way experienced clinical reviewers evaluate complex claims.
According to Pierre, the platform incorporates deep human expertise into machine intelligence so that each decision contributes to improving future analyses.
This continuous learning approach reflects Machinify’s broader vision of developing AI systems capable of adapting alongside the growing complexity of healthcare.
As precision medicine expands into additional therapeutic areas, machine intelligence may become increasingly valuable in supporting healthcare organizations facing rapidly changing clinical evidence.
Applying Clinical Knowledge in Real Time
The genetic testing capability combines several layers of information when evaluating claims.
The platform analyzes:
- Specialized genetic testing knowledge
- Clinical evidence
- Individual payer medical policies
- Contractual reimbursement rules
- Patient-specific clinical context
Rather than relying solely on billing codes, the AI considers the broader medical circumstances surrounding each claim.
This contextual analysis supports more informed reimbursement decisions while helping reduce unnecessary manual review.
Because every health plan maintains unique coverage policies, the platform adapts its evaluations according to each organization’s specific requirements.
This flexibility allows insurers to maintain policy consistency while improving operational efficiency.
Supporting Multiple Healthcare Programs
Machinify’s platform has been developed to support a wide range of healthcare payers.
Its AI models are currently designed for use across:
- Medicare
- Medicaid
- Commercial health insurance plans
Each of these programs presents distinct reimbursement requirements and regulatory expectations.
By incorporating payer-specific policies into its evaluation process, the platform helps organizations manage diverse payment environments while maintaining consistency across large claim volumes.
The ability to support multiple payer types broadens the platform’s applicability throughout the healthcare ecosystem.
Oversight by Clinical Specialists
Although artificial intelligence performs much of the analytical work, Machinify emphasizes that its models remain grounded in clinical expertise.
The company’s board-certified geneticists and clinical specialists oversee model development, validation, and ongoing governance.
This expert oversight helps ensure that AI-generated determinations remain clinically appropriate while reflecting current medical evidence.
Continuous review also enables the platform to incorporate emerging scientific discoveries as precision medicine continues evolving.
The integration of clinical governance strengthens confidence in the system’s recommendations while supporting responsible AI deployment within healthcare.
Transparency and Auditability
Healthcare payment decisions frequently require extensive documentation to satisfy regulatory requirements and internal compliance standards.
Machinify designed its genetic testing capability with transparency as a central principle.
Every payment determination generated by the platform is:
- Transparent
- Defensible
- Fully auditable
Rather than functioning as an opaque “black box,” the system provides clear reasoning supporting each reimbursement decision.
This transparency enables health plans to understand why claims were approved, denied, or flagged for additional review.
Auditability also supports compliance efforts by providing documentation that can be referenced during internal reviews or external regulatory examinations.
Demonstrating Real-World Financial Impact
The platform has already demonstrated measurable financial benefits in operational settings.
According to Machinify, one Medicaid program utilizing the genetic testing capability identified more than $70 million in savings across reproductive genetic testing and pharmacogenomic testing.
In addition to recovering unnecessary expenditures, the platform also improved payment accuracy for future claims involving these specialized services.
These results illustrate how AI-supported payment integrity can simultaneously reduce healthcare costs while improving reimbursement consistency.
As healthcare spending on genetic testing continues increasing, organizations are expected to place greater emphasis on technologies capable of managing this rapidly expanding category.
Continued Investment in Complex Payment Solutions
Tom Magnotta, President of Complex Payment Solutions at Machinify, noted that specialty clinical areas such as genetic testing are becoming increasingly important as scientific innovation accelerates.
He explained that both the volume of testing and associated healthcare expenditures have grown substantially over recent years.
To address these changes, Machinify continues investing in expanding the clinical content available within its payment intelligence platform.
Genetic testing represents only one component of the company’s broader strategy to apply artificial intelligence across increasingly complex healthcare payment scenarios.
Future platform enhancements are expected to extend into additional specialty areas where traditional payment integrity methods struggle to keep pace with evolving clinical practice.
Flexible Deployment Options
Health plans can implement the genetic testing capability in multiple ways depending on their operational requirements.
The solution is currently available through:
Real-Time Pre-Payment Review
Claims are evaluated before reimbursement occurs, enabling organizations to prevent incorrect payments while reducing unnecessary downstream recovery efforts.
Post-Payment Recovery
For organizations conducting retrospective payment analysis, the platform can identify overpayments requiring recovery after claims have already been processed.
Supporting both workflows provides flexibility for health plans at different stages of payment integrity modernization.
The Expanding Role of AI in Healthcare Administration
Artificial intelligence has increasingly become an important tool not only in clinical care but also in healthcare administration.
While AI frequently attracts attention for applications involving diagnostics and patient treatment, administrative functions such as payment integrity also present significant opportunities for improvement.
Healthcare payment systems involve millions of highly complex transactions requiring evaluation against constantly evolving clinical evidence, reimbursement policies, and contractual agreements.
Automating these processes through clinically informed AI has the potential to reduce administrative costs while improving consistency and accuracy.
Machinify’s expansion into genetic testing reflects the broader trend toward applying intelligent automation across increasingly specialized areas of healthcare operations.
The addition of genetic testing expertise to Machinify’s payment intelligence platform marks another important advancement in the application of artificial intelligence to healthcare administration. As precision medicine continues to expand and the number of available genetic tests grows rapidly, health plans face increasing challenges in evaluating complex claims accurately and efficiently.
By combining AI with decades of specialized clinical expertise acquired through InformedDNA’s payment integrity business, Machinify aims to help healthcare organizations navigate this complexity while improving payment accuracy, reducing unnecessary expenditures, and maintaining transparency throughout the reimbursement process.
With demonstrated savings in Medicaid programs, comprehensive clinical governance, and flexible deployment across pre-payment and post-payment workflows, the company’s latest capability positions Machinify to support health plans as precision medicine becomes an increasingly important component of modern healthcare. As genetic testing continues evolving, AI-driven payment intelligence may play a central role in ensuring that reimbursement decisions keep pace with scientific innovation while promoting more efficient and sustainable healthcare systems.
Source link: https://www.businesswire.com/
